Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience.
Sanchez AM, De Lauretis F, Bucaro A, Borghesan N, Pirrottina CV, Franco A, Scardina L, Giannarelli D, Millochau JC, Parapini ML, Di Leone A, Marazzi F, Orlandi A, Palazzo A, Fabi A, Masetti R, Franceschini G. Sanchez AM, et al. Among authors: giannarelli d. J Clin Med. 2024 Jun 23;13(13):3665. doi: 10.3390/jcm13133665. J Clin Med. 2024. PMID: 38999231 Free PMC article.
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L, Orlandi A, Palazzo A, Garufi G, Fabi A, Daniele G, Giannarelli D, Tortora G, Bria E. Mastrantoni L, et al. Among authors: giannarelli d. EClinicalMedicine. 2023 Jan 20;56:101824. doi: 10.1016/j.eclinm.2023.101824. eCollection 2023 Feb. EClinicalMedicine. 2023. PMID: 36713467 Free PMC article.
Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting.
Franco A, Di Leone A, Fabi A, Belli P, Carbognin L, Gambaro E, Marazzi F, Mason EJ, Mulè A, Orlandi A, Palazzo A, Paris I, Rossi A, Scardina L, Terribile DA, Tiberi G, Giannarelli D, Scambia G, Masetti R, Franceschini G. Franco A, et al. Among authors: giannarelli d. Cancers (Basel). 2023 Apr 25;15(9):2450. doi: 10.3390/cancers15092450. Cancers (Basel). 2023. PMID: 37173916 Free PMC article.
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: giannarelli d. NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2. NPJ Breast Cancer. 2023. PMID: 37684252 Free PMC article.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: giannarelli d. NPJ Breast Cancer. 2023 Oct 30;9(1):89. doi: 10.1038/s41523-023-00596-1. NPJ Breast Cancer. 2023. PMID: 37903774 Free PMC article. No abstract available.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: giannarelli d. NPJ Breast Cancer. 2024 Feb 5;10(1):13. doi: 10.1038/s41523-024-00619-5. NPJ Breast Cancer. 2024. PMID: 38316819 Free PMC article. No abstract available.
Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) - A multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Study Group.
Chiloiro G, Romano A, Mariani S, Macchia G, Giannarelli D, Caravatta L, Franco P, Boldrini L, Arcelli A, Bacigalupo A, Belgioia L, Fontana A, Meldolesi E, Montesi G, Niespolo RM, Palazzari E, Piva C, Valentini V, Gambacorta MA. Chiloiro G, et al. Among authors: giannarelli d. Clin Transl Radiat Oncol. 2023 Jan 12;39:100579. doi: 10.1016/j.ctro.2023.100579. eCollection 2023 Mar. Clin Transl Radiat Oncol. 2023. PMID: 36935859 Free PMC article.
Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
Marchetti C, Giannarelli D, Vizzielli G, Ferrandina G, Tortorella L, Fanfani F, Costantini B, Pasciuto T, Scambia G, Fagotti A. Marchetti C, et al. Among authors: giannarelli d. BJOG. 2023 Dec;130(13):1579-1588. doi: 10.1111/1471-0528.17558. Epub 2023 Jun 19. BJOG. 2023. PMID: 37334772 Clinical Trial.
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study.
Nelli F, Fabbri A, Virtuoso A, Giannarelli D, Marrucci E, Fiore C, Giron Berrios JR, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Caterini L, Farinelli S, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: giannarelli d. Clin Exp Med. 2024 Jan 20;24(1):13. doi: 10.1007/s10238-023-01263-2. Clin Exp Med. 2024. PMID: 38244147 Free PMC article.
616 results